Improvement of dyskinesias with l-dopa infusion in advanced Parkinson's disease

Acta Neurologica Scandinavica

Volumn 133, Issue 6, 2016, Pages 451-458

  Timpka, J ^a   Fox, T ^b   Fox, K ^b   Honig, H ^b   Odin, P ^a,b   Martinez Martin, P ^c   Antonini, A ^d   Ray Chaudhuri, K ^e  

^a LUND UNIVERSITY   (Sweden)

^b Central Hospital   (Germany)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d IRCCS SAN CAMILLO HOSPITAL   (Italy)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Continuous dopaminergic stimulation; Dyskinesias; Levodopa carbidopa intestinal gel; Motor complications; Movement disorders; Parkinson's disease; Quality of life; Treatment

Indexed keywords

CARBIDOPA PLUS LEVODOPA; LEVODOPA; ANTIPARKINSON AGENT; CARBIDOPA;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DYSKINESIA; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; MALE; MIDDLE AGED; MOTOR PERFORMANCE; PARKINSON DISEASE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PILOT STUDY; QUALITY OF LIFE; SELF EVALUATION; VISUAL ANALOG SCALE; VIVID DREAM; DYSKINESIAS; PARENTERAL DRUG ADMINISTRATION;

AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DYSKINESIAS; FEMALE; HUMANS; INFUSIONS, PARENTERAL; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; QUALITY OF LIFE;

EID: 84941312569     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12483     Document Type: Article

References (36)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58.
2. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-305.
3. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87.
4. De la Fuente-Fernandez R, Sossi V, Huang Z. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004;127(Pt 12):2747-54.
5. Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20:262-5.
6. Katzenschlager R, Hughes A, Evans A et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-7.
7. Kanovsky P, Kubova D, Bares M et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 2002;17:188-91.
8. Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
9. Weaver FM, Follett K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301:63-73.
10. Follett KA. Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias. Neurosurg Focus 2004;17:E3.
11. Olanow CW, Kieburtz K, Odin P et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13:141-9.
12. Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, GLORIA study investigators and coordinators. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 2015;21:231-5.
13. Nyholm D, Askmark H, Gomes-Trolin C et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-63.
14. Slevin JT, Fernandez HH, Zadikoff C et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients. J Parkinson's Dis 2015;5:165-74.
15. Fernandez HH, Standaert DG, Hauser RA et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord 2015;30:500-9.
16. Parkin SG, Gregory RP, Scott R et al. Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: a case series of 115 patients. Mov Disord 2002;17:682-92.
17. Eggert K, Oertel W, Reichmann H. Parkinson-Syndrome - Diagnostik und Therapie. Deutsche Gesellschaft für Neurologie 2012; [Internet] http://www.awmf.org/uploads/tx_szleitlinien/030-010l_S2k_Parkinson-Syndrome_Diagnostik_Therapie_2012_verlaengert.pdf. (Accessed Jun 1 2015).
18. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand 2001;104:343-8.
19. Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Langstrom B. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Neurology 1996;46:1430-6.
20. Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson's disease. Neurology 1998;51(Suppl 2):S30-5.
21. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55(Suppl 1):1-9.
22. Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508.
23. Stocchi F, Rascol O, Kieburtz K et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18-27.
24. Nyholm D, Nilsson Remahl AI, Dizdar N. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-23.
25. Isacson D, Bingefors K, Kristiansen IS, Nyholm D. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand 2008;118:379-86.
26. Antonini A, Mancini F, Canesi M et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 2008;5:244-6.
27. Puente V, de Fabregues O, Oliveras C et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010;16:218-21.
28. Martinez-Martin P, Reddy P, Katzenschlager R et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in parkinson's disease. Mov Disord 2015;30:510-6.
29. Peto V, Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. Age Ageing 2001;30:299-302.
30. Hechtner MC, Vogt T, Zollner Y et al. Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord 2014;20:969-74.
31. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20:224-30.
32. Devos D, French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009;24:993-1000.
33. Antonini A, Isaias IU, Canesi M et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-9.
34. Eggert K, Schrader C, Hahn M et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-66.
35. Honig H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74.
36. Caceres-Redondo MT, Carrillo F, Lama MJ et al. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease. J Neurol 2014;261:561-9.